SCHEMBL4841467

SCHEMBL4841467

O=C(COc1ccccc1)N1CCc2ccccc2C1CCN1CCC(c2ccc(Cl)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.46
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
DRD1 P21728 1/20 0.42
DRD5 P21918 1/20 0.42
HTR2A P28223 1/20 0.42
DRD3 P35462 1/20 0.42
CPT2 P23786 3/20 0.42
CPT1A P50416 3/20 0.42
CPT1B Q92523 1/20 0.41
S1PR1 P21453 1/20 0.41
PRCP P42785 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838758 0.84 MCHR1 (0.46) MCHR1DRD2DRD3PRCP
SCHEMBL4839157 0.81 ALDH1A1 (0.52) MCHR1DRD2PRCP
SCHEMBL4838819 0.81 NPSR1 (0.53) MCHR1DRD2
SCHEMBL4836850 0.81 NPSR1 (0.53) MCHR1DRD2
SCHEMBL4839404 0.80 MCHR1 (0.46) MCHR1DRD2PRCP
SCHEMBL4841563 0.79 DRD2 (0.54) MCHR1HTR1ADRD2DRD1DRD5
SCHEMBL4833495 0.75 ALDH1A1 (0.55) L3MBTL1
SCHEMBL4839745 0.75 MCHR1 (0.46) MCHR1DRD2
SCHEMBL4835975 0.74 NPSR1 (0.57) L3MBTL1
SCHEMBL4837767 0.73 DRD2 (0.54) MCHR1HTR1ADRD2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 MCHR1 2397/4885TDP1 4094/4885L3MBTL1 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.